Additionally, the OS benefit from GO2 observed among the group without adverse cytogenetics or TP53-mutated AML (Figure 1) was lost when the data of patients were censored at ASCT (Figure 5B). This evidence concerns the gene TP53 and acute myeloid leukemia.